9/13/2013 | PP | Cell Therapeutics plans $15 million registered offering of preferreds
|
3/28/2013 | PP | Cell Therapeutics secures $15 million through senior secured term loan
|
10/5/2012 | CV | New Issue: Cell Therapeutics sells upsized $60 million convertible preferreds
|
10/4/2012 | CV | Cell Therapeutics plans $40 million convertible preferred shares
|
10/4/2012 | CV | Market Commentary: New Ares Capital flat after pricing at discount; WellPoint gains; NuVasive loses on hedge
|
8/2/2012 | CVHYPF | Cell Therapeutics files $150 million shelf for stock, debt, preferreds
|
7/31/2012 | PP | Cell Therapeutics seals $15 million of $40 million preferreds offering
|
5/29/2012 | PP | Cell Therapeutics plans $40 million registered offering of preferreds
|
12/19/2011 | CVLM | Cell Therapeutics pays $11.2 million, retires all 5.75% convertibles
|
12/9/2011 | PP | Cell Therapeutics plans $20 million registered offering of preferreds
|
10/25/2011 | CVHYPF | Cell Therapeutics files $100 million shelf for stock, debt, preferreds
|
6/30/2011 | PP | Cell Therapeutics to raise $30 million through offering of preferreds
|
5/2/2011 | CVLM | Cell Therapeutics retires 7.5% convertibles, leaving just one series
|
4/28/2011 | PP | Cell Therapeutics sells $15.97 million of preferreds through offering
|
2/18/2011 | PP | Cell Therapeutics to raise $24.96 million in preferred stock offering
|
1/13/2011 | PP | Cell Therapeutics prices $25 million registered offering of preferreds
|
10/20/2010 | PP | Cell Therapeutics arranges $21 million offering of preferred stock
|
7/27/2010 | PP | New Issue: Cell Therapeutics gives details on $4.06 million preferred stock sale
|
7/26/2010 | PP | New Issue: Cell Therapeutics plans $4.06 million preferred stock private placement
|
7/26/2010 | PP | Market Commentary: Triple 8 wraps stock, unit issue; Mission Oaks pockets $7 million; Fire River seals placement
|
7/1/2010 | CVLM | Cell Therapeutics to retire all remaining 4% convertible notes
|
5/26/2010 | CVLM | Cell Therapeutics swaps stock for $1.85 million of 4% convertibles
|
5/24/2010 | PP | New Issue: Cell Therapeutics to raise $21 million through preferred stock offering
|
5/24/2010 | PP | Market Commentary: Sterling adds Warburg as investor; Hamton Roads plans capital raise; R.G.I. seeks $90 million
|
5/20/2010 | CVLM | Cell Therapeutics agrees to exchange up to $30 million 4% convertibles
|
5/17/2010 | CVLM | Cell Therapeutics to issue shares in exchange for up to $30 million of 4% convertible notes
|
3/31/2010 | PP | New Issue: Cell Therapeutics aims to raise $20 million in preferred stock offering
|
3/31/2010 | PP | Market Commentary: Inmet seals C$500 million; Cell Therapeutics to sell preferreds; Northeast Bancorp plans sale
|
1/13/2010 | PP | New Issue: Cell Therapeutics to raise $30 million through preferred stock offering
|
8/19/2009 | PP | New Issue: Cell Therapeutics to raise $30 million in direct offering of preferreds
|
6/19/2009 | CV | Cell Therapeutics accepts $52.92 million of convertibles in exchange
|
6/17/2009 | CV | Cell Therapeutics holders tender 46.1% of convertibles in exchange
|
6/3/2009 | CV | Cell Therapeutics amends offer for convertibles to offer fixed payment
|
5/19/2009 | CV | Cell Therapeutics ups payment in exchange offer for up to $89.2 million of convertibles
|
5/12/2009 | CV | Cell Therapeutics begins exchange offer for $89.2 million convertibles in Dutch auction
|
5/11/2009 | CVPP | Cell Therapeutics to exchange up to $89.2 million of convertibles in modified Dutch auction
|
5/11/2009 | PP | New Issue: Cell Therapeutics arranges $20 million registered direct offering of equity units
|
4/23/2009 | SS | Cranshire buys 9 million shares of Cell Therapeutics for 7.1% stake
|
4/17/2009 | CVPP | Cell Therapeutics issues common shares for remaining preferred shares
|
4/13/2009 | PP | Market Commentary: Paramount Energy to sell special warrants; Neostem raises $11 million; Javo earns $22.5 million
|
4/13/2009 | PP | New Issue: Cell Therapeutics to raise $20 million via direct offering of convertible preferreds
|
2/5/2009 | CV | Cell Therapeutics exchanges 83% of convertible preferreds
|
12/5/2008 | CV | Cell Therapeutics board OKs modified Dutch auction offer for five series of convertibles
|
12/4/2008 | PP | New Issue: Cell Therapeutics to sell $38.65 million of convertible notes in direct offering
|
10/21/2008 | PP | New Issue: Cell Therapeutics offers $24.7 million in convertibles to single investor
|
9/26/2008 | PP | New Issue: Cell Therapeutics now to sell $14.21 million convertibles, stock
|
9/15/2008 | PP | New Issue: Cell Therapeutics plans $18 million placement of 10% convertibles
|
9/5/2008 | CVHY | Cell Therapeutics files $150 million stock, debt securities shelf
|
7/30/2008 | PP | New Issue: Cell Therapeutics negotiates $12 million equity line
|
7/24/2008 | PP | New Issue: Cell Therapeutics offers $44.5 million of convertible notes in warrant exercise
|
7/23/2008 | PP | New Issue: Cell Therapeutics to sell $22.25 million of convertible notes in warrant exercise
|
6/12/2008 | PP | New Issue: Cell Therapeutics to sell $23 million of convertible notes in private placement
|
4/30/2008 | PP | New Issue: Cell Therapeutics prices $45 million placement of units of preferreds, notes and warrants
|
4/30/2008 | PP | Market Commentary: Cell Therapeutics eyes cash for year; SulphCo get equity financing deal; Cadillac lands new shareholder
|
3/31/2008 | CVHY | Cell Therapeutics files $150 million shelf registration
|
3/4/2008 | CVPP | New Issue: Cell Therapeutics sells $51.66 million four-year convertibles to yield 9%, up 10%
|
3/4/2008 | PP | Market Commentary: Auction Floor sells $1.5 million of units; VeriChip raises $8 million; Cell Therapeutics sells convertibles
|
2/13/2008 | CV | Cell Therapeutics exchanges $9.1 million convertibles for stock
|
12/21/2007 | PP | New Issue: Cell Therapeutics announces $7 million direct placement of stock
|
12/20/2007 | PP | New Issue: Cell Therapeutics announces $7 million direct placement of stock
|
12/13/2007 | CV | Cell Therapeutics issues $23.25 million 5.75% convertibles, shares in exchange for $36.1 million notes
|
11/30/2007 | PP | New Issue: Cell Therapeutics prices $6.5 million of preferreds
|
11/26/2007 | CV | Market Commentary: Countrywide, Fannie Mae, E*Trade down as financials tumble; SunPower, Suntech Power brighten dark day
|
8/29/2007 | PP | Cell Therapeutics amends series C preferreds to meet Nasdaq rule
|
7/27/2007 | PP | Market Commentary: Advanced Viral Research sells $2.75 million in convertibles; Cell Therapeutics shares dip
|
7/26/2007 | PP | New Issue: Cell Therapeutics plans $20.25 million convertible preferreds direct placement
|
7/26/2007 | PP | Market Commentary: Cell Therapeutics to wrap $20.25 million offering; Sport Supply secures $18.3 million
|
6/1/2007 | CVHY | Cell Therapeutics files $150 million shelf
|
4/13/2007 | PP | Market Commentary: Novelos Therapeutics secures $15 million from preferreds; EnerJex closes $9 million PIPE
|
4/12/2007 | PP | New Issue: Cell Therapeutics to sell $37.2 million convertible preferreds
|
4/12/2007 | PP | Market Commentary: Cell Therapeutics secures $37.2 million from PIPE; American Oil to raise $28.5 million in stock sale
|
2/14/2007 | PP | New Issue: Cell Therapeutics to sell $2.36 million convertible preferreds
|
2/12/2007 | SS | Market Commentary: Four Seasons, Hilton, Starwood slide; Southwest soars; Eddie Bauer off; WCI up; Onyx rockets
|
2/9/2007 | PP | Market Commentary: Kosan secures $45.5 million from stock sale; DOR raises $5.49 million
|
2/8/2007 | PP | New Issue: Cell Therapeutics to sell $17.6 million convertible preferreds
|
2/8/2007 | PP | Market Commentary: Cell Therapeutics secures $17.6 million from placement; Genelabs to close $10 million stock offering
|
1/31/2007 | SS | Cell Therapeutics needs Italian shareholders for quorum, decision on increasing authorized shares
|
1/19/2007 | SS | DOR BioPharma gets unsolicited acquisition proposal from Cell Therapeutics
|
11/7/2006 | BT | Cell Therapeutics: third-quarter net loss up almost $20 million from prior-year period
|
10/18/2006 | BTPP | Cell Therapeutics repurchases stock to comply with Nasdaq rules
|
9/20/2006 | PP | Market Commentary: Solexa seals $75 million equity line; Alberta Clipper prices, upsizes PIPE for C$25 million
|
9/19/2006 | BT | Market Commentary: Novavax slips; GenVec steady; Cell Therapeutics drops 16%; ImClone off; Vasogen up 12%
|
9/19/2006 | PP | Market Commentary: Cell Therapeutics to seal $40 million direct stock sale; Petra Diamonds pockets $20 million from bonds
|
9/19/2006 | BTPP | New Issue: Cell Therapeutics gets $40 million from direct placement of stock
|
9/18/2006 | BTPP | New Issue: Cell Therapeutics to sell $15 million of stock to Novartis
|
9/18/2006 | BT | Cell Therapeutics, Novartis to develop Xyotax in lung cancer
|
9/18/2006 | BT | Market Commentary: Genentech steady on Glaxo filing; Cell Therapeutics, Inovio gain on deals; MannKind up, Nektar down
|
9/18/2006 | PP | Market Commentary: Cell Therapeutics stock up 6.67% on $15 million Novartis deal; Inovio gears up to close two offerings
|
9/6/2006 | BT | Market Commentary: Genta plummets another 41%; Genomic Health falls 17%; Cell Therapeutics up 8%; Anadys up
|
8/23/2006 | CV | Market Commentary: Gateway climbs on offer; Developers REIT deal falls flat; Cell leaps on trial data; Ford picks up speed
|
8/23/2006 | BT | Cell Therapeutics: Xyotax and radiation produces major responses in 91% of cancer patients
|
8/23/2006 | BT | Market Commentary: Cell Therapeutics' stock takes off on positive phase 1 data; Cubist's stock up again on Theravance news
|
8/8/2006 | BT | Cell Therapeutics net loss shrinks by 42% during second quarter to $0.20 per share
|
8/8/2006 | BT | Cell Therapeutics: Monitoring committee says pixantrone trial should continue
|
6/23/2006 | BTPP | New Issue: Cell Therapeutics releases terms on €45 million equity line
|
6/21/2006 | BT | Market Commentary: Cell Therapeutics gains on equity financing; Arena higher on data; MedImmune airs $1 billion bond deal
|
6/21/2006 | BTPP | Cell Therapeutics secures €45 million equity line
|
6/7/2006 | BT | Cell Therapeutics: path for Xyotax approval in U.S., Europe now clear
|
6/6/2006 | BT | Cell Therapeutics: Stellar trials show Xyotax impacts lung cancer survival rate in women
|
6/1/2006 | BT | Cell Therapeutics, FDA agree on NDA filing strategy for Xyotax
|
5/22/2006 | BT | Market Commentary: Adventrx gains after pulling deal; Dyax gains, Icos slips on pact; Cell Therapeutics declines 7%
|
5/18/2006 | BT | Market Commentary: Neurocrine piles on more losses; DOV adds back 10%; Celgene sees buying on dip; Exelixis up
|
5/16/2006 | BT | Cell Therapeutics: Pixantrone combination produces 77% complete tumor disappearance in lymphoma patients
|
4/25/2006 | CV | Market Commentary: Serologicals weakens on hedged basis; JetBlue, Level 3 gain on results; Dov falls on drug trial woes
|
4/25/2006 | BTCV | New Issue: Cell Therapeutics prices $33.2 million of 5-year convertibles at 7.5%, up 15%
|
4/11/2006 | BT | Market Commentary: NitroMed, Antigenics strike new lows; NPS Pharma, Insmed gain; Medtronic deal boosts Biomet
|
4/10/2006 | BT | Cell Therapeutics granted U.S. patent for new class of small antitubulin agents to fight cancer
|
4/7/2006 | BT | Market Commentary: Medarex slides; Biomet gains on anticipated sale; Cell Therapeutics higher; Acusphere dives on PIPE
|
4/6/2006 | CV | Market Commentary: Allergan new deal stumbles in the gray; Annaly offering seen as hedge play; Cell Therapeutics plans deal
|
4/6/2006 | BTCV | Cell Therapeutics plans $50 million to $100 million convertible sale or exchange
|
3/22/2006 | BT | Cell Therapeutics' CPOP trial shows pixantrone offers improved rates of remission
|
3/9/2006 | BT | Cell Therapeutics says net loss shrinks to $102.5 million in 2005
|
3/9/2006 | BT | Market Commentary: NPS Pharma weak ahead of FDA; Dyax plunges; Insmed up slightly; Vertex dives; Elan off, Biogen up
|
2/8/2006 | BT | Market Commentary: Pfizer news sparks buyout buzz; Immtech falls; Alkermes up; Icos off; Alexion higher; Oscient down
|
2/8/2006 | CV | Market Commentary: Citadel retraces some gains; Qwest flat but adds on hedge; MGI better; Oil States lower; Pier 1 prices
|
2/3/2006 | BTCV | Cell Therapeutics files $150 million debt, stock shelf
|
12/6/2005 | BT | Cell Therapeutics to begin Xyotax trial in women with lung cancer
|
11/9/2005 | BT | Cell Therapeutics: Rituxan/pixantrone combination significantly improves response in lymphoma patients
|
11/4/2005 | BT | Market Commentary: Introgen's stock lifts on Colgate-Palmolive alliance; Cytori, Olympus enter into joint venture
|
11/1/2005 | BTCV | New Issue: Cell Therapeutics $82 million five-year convertibles yield 6.75%, up 10%
|
11/1/2005 | BT | Market Commentary: Cell Therapeutics prices $82 million notes to yield 6.75%; Nabi's stock dives on failed clinical trial
|
11/1/2005 | CV | Market Commentary: Qwest, Chesapeake Energy to price $2 billion-plus in convertibles; new IPC paper trades actively
|
10/27/2005 | BT | Market Commentary: NxStage soars on IPO debut; Durect launches equity deal; Cell Therapeutics deal abuzz; Amylin plunges
|
10/27/2005 | PP | Market Commentary: MetaSolv pockets $23 million from unit deal; proposed Cell Therapeutics convertible talked at 6.75%
|
9/2/2005 | BT | Market Commentary: Cell Therapeutics plunges on auditor departure; Amylin shares off on profit taking; Watson off
|
8/24/2005 | BT | Cell Therapeutics kept by Stanford at buy
|
6/13/2005 | BT | Cephalon acquires cancer drug Trisenox from Cell Therapeutics in up to $170 million deal
|
6/13/2005 | CV | Market Commentary: Invitrogen launches $300 million convertible; Connetics, Cephalon stir market; Northwest hits turbulence
|
3/7/2005 | CV | Market Commentary: Genworth synthetic coming; Cell Therapeutics dives; Celgene rises; Saks bagged up; Lions Gate higher
|
12/20/2004 | PP | New Issue: Cell Therapeutics raises $18.4 million in direct placement of shares
|
6/18/2003 | CV | Market Commentary: CNet pulled, other new deals sweetened; Reliant upsizes as buyers reach for a fat coupon
|
6/18/2003 | CV | New Issue: Cell Therapeutics downsized $75 million convertibles at 4.0% yield, up 23.5%
|
6/17/2003 | CV | Cell Therapeutics $100 million overnighter talked to yield 3.5-4.0%, up 25-30%
|
6/17/2003 | CV | Market Commentary: New deal parade marches on; Lattice reoffered at 98, still dives; secondary thin, lower
|
3/26/2003 | CV | Deutsche analysts say many of convertibles with worst up/down profiles have short-dated puts
|
2/26/2003 | CV | Market Commentary: New issues bid up in gray; Tyco's new converts gain sharply, power names dive
|
1/7/2003 | CV | Market Commentary: Heavy trading on Tyco deal; InterMune dives, techs and telecoms soar, power mixed
|
12/19/2002 | CV | Market Commentary: Market settles back into slow, holiday-like mode
|
12/18/2002 | CV | Cell Therapeutics says $145.36 million convertibles tendered in exchange
|
12/17/2002 | CV | Market Commentary: Market remains quiet as two small deals price, stocks slip
|
11/20/2002 | CV | Market Commentary: Xcel's new deal screams higher while others edge up, languish
|
11/19/2002 | CV | Cell Therapeutics offers to exchange convertibles for fewer notes with lower conversion price
|
9/4/2002 | CV | Market Commentary: Market tone improves but still patchy; Symantec, Calpine gain
|
6/12/2002 | CV | Deutsche on biopharma: buy Inhale, Cell Therapeutics; hold Abgenix, Alexion; sell Vertex, ISIS
|
5/20/2002 | CV | Market Commentary: Buyers emerge for downtrodden Adelphia, Lucent, energy traders; biotechs fall amid profit taking
|
12/7/2001 | CV | Market Commentary: Convertible market slides as stock enthusiasm withers, no new deals
|
11/27/2001 | CV | Market Commentary: Convertible market seen flat on heavy trading from high volatility
|